- Home
- SRZN vs PRQR Comparison
SRZN vs PRQR Comparison
Compare SRZN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | PRQR |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | Netherlands |
| Employees | 59 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.6M | 262.5M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SRZN | PRQR |
|---|---|---|
| Price | $22.42 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $38.00 | $7.25 |
| AVG Volume (30 Days) | 255.4K | ★ 972.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,477,000.00 | N/A |
| Revenue This Year | $75.35 | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.30 | $1.33 |
| 52 Week High | $35.00 | $3.10 |
Technical Indicators
Market Signals| Indicator | SRZN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 63.66 |
| Support Level | $20.26 | $1.40 |
| Resistance Level | $24.13 | $2.44 |
| Average True Range (ATR) | 1.40 | 0.15 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 8.67 | 72.39 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.